HealthJohnson & Johnson Reports 75% Response Rate in 50-mg Phase 1 Prostate Cancer CohortBy Naomi CalderOct 26, 2026, 7:14 PM UTC
HealthJohnson & Johnson Reports Early JNJ-6143 Responses in Prostate Cancer TrialBy Naomi CalderOct 24, 2026, 6:21 PM UTC
HealthStudy Links Apalutamide Before and After Surgery to Lower Event HazardBy Naomi CalderOct 24, 2026, 3:21 PM UTC
HealthMyeloma Foundation Launches U.S. Trial Network With Johnson & JohnsonBy Naomi CalderOct 22, 2026, 10:15 PM UTC
BusinessJohnson & Johnson Veteran Chuck Austin To Scale Up BioSig OperationsBy Nasdaq OMXJan 9, 2018, 1:00 PM UTC
BusinessCURE Pharmaceutical Strengthens Senior Leadership Team with Appointment of Industry Veteran Richard Serbin as Head of Global Corporate DevelopmentBy Nasdaq OMXMay 9, 2017, 1:02 PM UTC
BusinessCURE Pharmaceutical Strengthens Senior Leadership Team with Appointment of Industry Veteran Richard Serbin as Head of Global Corporate DevelopmentBy Nasdaq OMXMay 9, 2017, 1:02 PM UTC
BusinessCURE Pharmaceutical Strengthens Senior Leadership Team with Appointment of Industry Veteran Richard Serbin as Head of Global Corporate DevelopmentBy Nasdaq OMXMay 9, 2017, 1:02 PM UTC
